hepatic focal nodular hyperplasia
Conditions
Interventions
Control group :TAE with iodinated oil emulsion
interventional group:TAE with bleomycin hydrochloride-iodized oil emulsion
Sponsors
The First Medical Center of the General Hospital of the Chinese People's Liberation Army
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 50 years; 2. Pathological diagnosis of FNH; 3. Complete clinical, laboratory and imaging data; 4. Accompanied by abdominal pain, abdominal distension, low back pain and other symptoms, the medical treatment is invalid, which obviously affects the quality of life; 5. ECOG-PS score 0-1 points; 6. There are no other contraindications for angiography (such as contrast agent allergy, uncontrolled infection, uncorrectable coagulation disorder, etc.); 7. The subjects voluntarily joined the study, signed the informed consent, and were able to cooperate with the follow-up and complete the research project.
Exclusion criteria
Exclusion criteria: 1. Severe abnormal liver function (ALT/AST>=4ULN, DBIL>=3ULN) 2. Abnormal coagulation function (INR>1.5 or prothrombin time (PT)>ULN+4 seconds), with bleeding tendency or receiving thrombolytic or anticoagulation therapy; 3. Patients with grade II and above myelosuppression; 4. Active period of infectious disease; 5. Those with severe heart, lung, kidney, brain and other underlying diseases who cannot tolerate interventional therapy; 6. Those who cannot tolerate a complete treatment cycle (>=2 times) and cannot objectively evaluate the efficacy; 7. Menstrual period women wait until the end of the menstrual period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| disease control rate; | — |
Countries
China
Contacts
Public ContactWang Maoqiang
The First Medical Center of the General Hospital of the Chinese People's Liberation Army
Outcome results
None listed